Design Therapeutics (DSGN) Total Liabilities (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Total Liabilities of $13.3 million for Q2 2026, up 34.74% year-over-year from $9.8 million in Q2 2025, and up 7.13% on a QoQ basis from $12.4 million in Q1 2026.
Design Therapeutics (DSGN) Total Liabilities (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $13.3 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $13.3 million, up 34.74% year-over-year; the trailing twelve-month figure through Jun 2026 was $13.3 million (up 34.74% YoY), and the FY2025 annual result was $13.7 million, up 37.05% from the prior year.
- Total Liabilities rose to $13.3 million in Q2 2026, from $12.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $14.9 million in Q3 2023 and troughed at $8.3 million in Q2 2024.
- A 5-year average of $11.6 million and a median of $11.9 million in 2023 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2022, when Total Liabilities soared 203.78%; it then sank 43.78% in 2024.
- A 5-year view of Total Liabilities shows it stood at $13.8 million in 2022, then retreated by 13.53% to $12.0 million in 2023, then declined by 16.39% to $10.0 million in 2024, then surged by 37.05% to $13.7 million in 2025, then decreased by 3.13% to $13.3 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $13.3 million in Q2 2026, $12.4 million in Q1 2026, and $13.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 13.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.27 Mn |
| Mar 31, 2026 | 12.39 Mn |
| Dec 31, 2025 | 13.70 Mn |
| Sep 30, 2025 | 12.05 Mn |
| Jun 30, 2025 | 9.85 Mn |
| Mar 31, 2025 | 9.56 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 9.18 Mn |
| Jun 30, 2024 | 8.34 Mn |
| Mar 31, 2024 | 9.24 Mn |
| Dec 31, 2023 | 11.96 Mn |
| Sep 30, 2023 | 14.91 Mn |
| Jun 30, 2023 | 14.84 Mn |
| Mar 31, 2023 | 11.93 Mn |
| Dec 31, 2022 | 13.83 Mn |
| Sep 30, 2022 | 13.63 Mn |
| Jun 30, 2022 | 10.77 Mn |
| Mar 31, 2022 | 8.49 Mn |
| Dec 31, 2021 | 8.43 Mn |
| Sep 30, 2021 | 8.79 Mn |